Marinus Pharmaceuticals Reduces Workforce Amidst Challenges in Epilepsy Treatment Development

1. Marinus Pharmaceuticals, a biopharmaceutical company focused on developing treatments for epilepsy and other neurological disorders, has announced a 20% reduction in its workforce.
2. The decision to lay off employees comes as the company faces challenges in the development of its epilepsy treatment, ganaxolone.
3. Ganaxolone, an investigational neuroactive steroid, has been undergoing clinical trials for the treatment of epilepsy, but results have not met expectations.
4. The workforce reduction is part of a broader financial restructuring effort aimed at extending the company's cash runway and focusing resources on key priorities.
5. Marinus Pharmaceuticals remains committed to advancing the development of ganaxolone and exploring its potential in other neurological disorders.
6. The company plans to provide updates on its progress and financial status in future communications.